Cybin (NASDAQ:HELP) Insider Eric So Buys 100,000 Shares of Stock

Posted by Geri Gentry on Sep 11th, 2026

Cybin Inc. (NASDAQ:HELP – Get Free Report) insider Eric So acquired 100,000 shares of Cybin stock in a transaction dated Tuesday, September 8th. The shares were acquired at an average cost of $12.39 per share, with a total value of $1,239,000.00. Following the completion of the acquisition, the insider directly owned 4,465,014 shares in the company, valued at $55,321,523.46. This trade represents a 2.29% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link.

Cybin Trading Up 1.6%

Shares of Cybin stock traded up $0.21 during midday trading on Friday, reaching $13.05. The company had a trading volume of 356,146 shares, compared to its average volume of 1,197,092. Cybin Inc. has a 1-year low of $3.76 and a 1-year high of $14.35. The company has a market capitalization of $986.41 million, a price-to-earnings ratio of -4.32 and a beta of 0.63. The stock has a fifty day simple moving average of $9.84 and a 200 day simple moving average of $6.85.

Cybin (NASDAQ:HELP – Get Free Report) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.11). Sell-side analysts expect that Cybin Inc. will post -2.95 earnings per share for the current year.

Key Cybin News

Here are the key news stories impacting Cybin this week:

Positive Sentiment: Insider buying is the primary near-term catalyst. Paul Glavine purchased 100,000 shares for approximately $1.18 million at an average price of $11.78, increasing his holdings by 2.46% to more than 4.17 million shares. He also bought 90,000 shares in late August. Cybin insider purchase report
Positive Sentiment: Insider Eric H. L. So acquired 100,000 shares for approximately $1.21 million at $12.09 per share, following a 95,000-share purchase earlier in September. The repeated open-market purchases by two insiders may reinforce investor confidence in Cybin’s outlook. SEC insider purchase filing
Positive Sentiment: Helus Pharma, Cybin’s commercial name, plans to participate in the Morgan Stanley Global Healthcare Conference on September 16, where CEO Michael Halstead is scheduled for a fireside chat. The event could increase visibility into the company’s psychedelic-based mental-health pipeline and upcoming clinical milestones. Morgan Stanley conference announcement
Neutral Sentiment: The latest short-interest report lists zero shares sold short and a zero-day days-to-cover ratio, but also contains an invalid “NaN” percentage change. As a result, it provides little dependable information about current short-selling pressure.
Negative Sentiment: Cybin continues to operate at a loss. Its latest quarterly loss of $0.91 per share was wider than the expected $0.80 loss, and analysts forecast a full-year loss of approximately $2.95 per share. The stock’s strong recent advance and lack of a new trial result or regulatory approval could also leave it vulnerable to profit-taking.

Wall Street Analysts Forecast Growth

HELP has been the subject of a number of research reports. Wall Street Zen raised Cybin from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 29th. TD Cowen boosted their price objective on shares of Cybin from $8.00 to $62.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Finally, Wells Fargo & Company assumed coverage on Cybin in a research note on Monday, July 27th. They issued an “overweight” rating and a $16.00 target price on the stock. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $48.60.

Get Our Latest Stock Analysis on HELP

Institutional Trading of Cybin

Hedge funds and other institutional investors have recently made changes to their positions in the business. Osaic Holdings Inc. grew its stake in shares of Cybin by 46.7% in the second quarter. Osaic Holdings Inc. now owns 7,543 shares of the company’s stock worth $63,000 after purchasing an additional 2,400 shares during the last quarter. AXQ Capital LP bought a new position in Cybin in the 2nd quarter valued at approximately $75,000. Bank of America Corp DE boosted its stake in shares of Cybin by 66.8% during the 2nd quarter. Bank of America Corp DE now owns 29,443 shares of the company’s stock worth $247,000 after acquiring an additional 11,790 shares during the last quarter. Pale Fire Capital SE purchased a new position in shares of Cybin during the 2nd quarter valued at about $1,015,000. Finally, Millennium Management LLC increased its stake in shares of Cybin by 1,388.5% in the fourth quarter. Millennium Management LLC now owns 1,028,549 shares of the company’s stock worth $8,414,000 after purchasing an additional 959,448 shares in the last quarter. 17.94% of the stock is currently owned by institutional investors and hedge funds.

About Cybin

(Get Free Report)

Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.